Your browser is no longer supported. Please, upgrade your browser.
Settings
NVS Novartis AG daily Stock Chart
NVS [NYSE]
Novartis AG
Index- P/E30.02 EPS (ttm)2.81 Insider Own9.30% Shs Outstand2.64B Perf Week1.92%
Market Cap222.88B Forward P/E15.99 EPS next Y5.28 Insider Trans0.09% Shs Float2.56B Perf Month1.73%
Income6.68B PEG4.78 EPS next Q1.20 Inst Own11.20% Short Float0.08% Perf Quarter-1.30%
Sales49.53B P/S4.50 EPS this Y-2.80% Inst Trans-0.27% Short Ratio1.15 Perf Half Y4.50%
Book/sh30.97 P/B2.73 EPS next Y9.63% ROA5.00% Target Price93.00 Perf Year19.07%
Cash/sh- P/C- EPS next 5Y6.28% ROE9.40% 52W Range69.53 - 86.90 Perf YTD15.97%
Dividend2.72 P/FCF39.37 EPS past 5Y-5.80% ROI7.30% 52W High-2.80% Beta0.76
Dividend %3.22% Quick Ratio0.80 Sales past 5Y-3.60% Gross Margin65.70% 52W Low21.49% ATR0.80
Employees121000 Current Ratio1.10 Sales Q/Q2.80% Oper. Margin16.20% RSI (14)50.26 Volatility0.79% 0.79%
OptionableYes Debt/Eq0.42 EPS Q/Q9.20% Profit Margin13.50% Rel Volume0.52 Prev Close84.66
ShortableYes LT Debt/Eq0.32 EarningsJan 23 BMO Payout95.80% Avg Volume1.72M Price84.47
Recom2.50 SMA200.25% SMA500.37% SMA2003.49% Volume890,999 Change-0.22%
Dec-06-17Downgrade BofA/Merrill Neutral → Underperform
Jul-26-17Upgrade Morgan Stanley Underweight → Overweight
Jul-05-17Downgrade Credit Suisse Neutral → Underperform
Mar-09-17Initiated Liberum Buy
Mar-08-17Upgrade Societe Generale Hold → Buy
Mar-07-17Downgrade Exane BNP Paribas Neutral → Underperform
Jan-11-17Downgrade Credit Suisse Outperform → Neutral
Nov-10-16Upgrade Argus Hold → Buy
Oct-10-16Reiterated Chardan Capital Markets Buy $95 → $92
Sep-20-16Initiated Chardan Capital Markets Buy $95
Apr-12-16Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-23-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Dec-13-17 12:31PM  ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More Benzinga
09:43AM  Novartis generics arm says may sell or end some products Reuters
Dec-12-17 05:39PM  Novartis Announces Positive Data on Sickle Cell Disease Drug Zacks
07:14AM  ASH 2017: CAR-T Wallops Blood Cancer Motley Fool
Dec-11-17 05:59PM  Novartis Reports Updated Results from Kymriah's JULIET Study Zacks
02:24PM  What's Causing Juno Therapeutics Shares to Tumble 11.9% Today Motley Fool
12:06PM  Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today Zacks
11:03AM  Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study PR Newswire
10:09AM  Gilead Sciences: Better Data, Better Stock? Barrons.com
05:11AM  These defensive stocks make the cut as one of Morgan Stanleys key picks for 2018 MarketWatch
Dec-10-17 06:13PM  Novartis CAR-T therapy leads to durable response in lymphoma study Reuters
10:30AM  Novartis CAR-T therapy leads to durable response in lymphoma study Reuters
Dec-08-17 07:51AM  Roche, Novartis' Italian heads risk trial for alleged market rigging: sources Reuters
Dec-07-17 03:27PM  Pfizer Reports Updated Data from Phase III Study on Ibrance Zacks
09:01AM  In Young Women With Metastatic Breast Cancer, Kisqali Delays Tumor Growth And Relieves Symptoms Forbes
07:00AM  Advanced Accelerator Applications Announces Commencement of Novartis Tender Offer GlobeNewswire
01:01AM  Novartis tender offer for Advanced Accelerator Applications commences GlobeNewswire
Dec-06-17 10:30AM  Analysts Recommendations for GlaxoSmithKline in November 2017 Market Realist
Dec-05-17 06:26PM  Australian watchdog takes GlaxoSmithKline, Novartis units to court Reuters
04:00PM  Advanced Accelerator Applications Board of Directors Recommends $3.9 Billion All Cash Tender Offer by Novartis GlobeNewswire
07:32AM  Novartis on the Street: Analyst Recommendations in November Market Realist
Dec-04-17 10:33AM  Behind Novartiss Developments as of November 2017 Market Realist
09:03AM  Inside Novartiss Alcon Performance in 3Q17 Market Realist
07:35AM  GlaxoSmithKlines Valuation in November 2017 Market Realist
07:34AM  Inside Novartiss Sandoz Performance in 3Q17 Market Realist
Dec-03-17 11:41AM  Mylan and Teva stocks rise on report about Amazons pharmacy aims MarketWatch
Dec-01-17 05:15PM  Inside Novartiss Innovative Medicines Business in 3Q17 Market Realist
03:45PM  Assessing Novartiss Revenues in 3Q17 Market Realist
02:11PM  Gauging Novartiss Valuation This November Market Realist
09:57AM  Citi Downgrades Regeneron, Citing 'Underappreciated' Risk Benzinga
08:49AM  Amazon Pharma Business Rumors Are Making Drug Stocks Go Crazy Fortune
07:00AM  3 Stocks to Watch on Friday: Novartis AG (ADR) (NVS), Nutanix Inc (NTNX) and Zumiez Inc. (ZUMZ) InvestorPlace
06:56AM  Amazon in Exploratory Talks with Generic-Drug Makers: Report Investopedia
Nov-30-17 05:49PM  Amazon Reportedly In Talks With Mylan, Novartis About Pharma Entry Investor's Business Daily
04:58PM  Amazon is in exploratory talks with generic-drug makers CNBC
07:30AM  Are Viruses a Problem for CAR-T Drugmakers? Motley Fool
Nov-28-17 10:35AM  Pharma's Paradox: Cure A Deadly Childhood Disease And Then Get Attacked On Price Forbes
Nov-27-17 10:45AM  Regeneron's Eylea Protection Is Weakening Bloomberg
07:54AM  The Zacks Analyst Blog Highlights: Johnson & Johnson, Novartis, GlaxoSmithKline and Roche Zacks
07:20AM  Regeneron drops eye-drug combination as Novartis chases Eylea Reuters
Nov-25-17 07:21AM  5 Cancer Types With the Poorest Long-Term Outlook Motley Fool
Nov-24-17 01:59PM  Cancer Space Update: 2 Drugs Receive Regulatory Nod in EU Zacks
08:38AM  Will New Drug Approvals Boost Novartis (NVS) Portfolio? Zacks
08:38AM  Pharma Stock Roundup: FDA Approves J&J, Glaxo HIV Drug, Roche Presents Data Zacks
Nov-23-17 09:00AM  Top 10 Largest Pharmaceutical Companies By Revenue in 2017 Insider Monkey
Nov-22-17 08:15AM  Novartis (NVS) Receives EC Nod for Tasigna Label Expansion Zacks
Nov-17-17 10:30AM  Novartis on the Street: Analysts Recommendations in November Market Realist
09:00AM  How Did Novartis Subsidiaries Alcon and Sandoz Perform in 3Q17? Market Realist
07:30AM  How 2 Key Novartis Oncology Drugs Performed in 3Q17 Market Realist
Nov-16-17 11:00AM  CMS Administrator Seema Verma To Outline Her Plan At 2017 Forbes Healthcare Summit Forbes
10:30AM  Behind 4 Key Novartis Money Makers (and Losers) in 3Q17 Market Realist
09:00AM  How Novartiss Tasigna Is Looking Now Market Realist
07:30AM  Behind Novartiss Entresto and Gilenya Performances in 3Q17 Market Realist
Nov-15-17 07:01PM  Pfizer, Novartis agree UK price cuts for new breast cancer drugs Reuters
10:31AM  Behind Novartiss Established Medicine Performance in 3Q17 Market Realist
09:01AM  Behind Novartiss Respiratory Drug Performance in 3Q17 Market Realist
07:32AM  Inside Novartiss Ophthalmology Drugs Now Market Realist
Nov-14-17 07:10PM  Regeneron CEO: Competitor Novartis is 'long on enthusiasm... CNBC Videos
06:59PM  Cramer Remix: My leftover question for GE is 'Did you mislead us or yourselves?' CNBC
05:25PM  How Novartiss Immunology and Dermatology Portfolio Looks after 3Q17 Market Realist
03:55PM  How Novartiss Cosentyx Is Positioned after 3Q17 Market Realist
02:21PM  How Did Novartis Perform in 3Q17? Market Realist
01:05PM  Behind Sanofis 3Q17 Revenue Growth Market Realist
08:31AM  Novartis (NVS) Arm's Biosimilars Study Results Encourage Zacks
07:34AM  3 Top Big Pharma Dividend Stocks You Can Buy Right Now Motley Fool
Nov-13-17 12:00PM  Novartis launches heart drug counter-offensive Reuters
Nov-12-17 09:09AM  Better Buy: Exelixis, Inc. vs. Novartis AG Motley Fool
Nov-10-17 05:42PM  Novartis posts eye drug data amid play for Eylea's turf Reuters
05:30PM  Novartis posts eye drug data amid play for Eylea's turf Reuters
03:30PM  Momenta Pharmaceuticals, Inc.'s Rough Month Motley Fool
Nov-09-17 09:16AM  Ophthotech (OPHT) Q3 Earnings & Sales Beat, Zimura in Focus Zacks
Nov-08-17 04:42AM  Novartis takes fight to Pfizer's Ibrance with new Kisqali data Reuters
Nov-07-17 01:08PM  Here's Why Advanced Accelerator Application SA Rose 20% in October Motley Fool
Nov-06-17 04:31PM  9 Notable Biotechs Presenting At This Year's ASH Meeting Benzinga
03:04PM  Bluebird: Can It Keep Singing? Barrons.com
12:12PM  ETFs with exposure to Novartis AG : November 6, 2017 Capital Cube
08:32AM  Pharma Stock Roundup: Pfizer, Teva's Q3 Earnings, Novartis Seeks New Indication for Kymriah Zacks
Nov-02-17 05:03PM  Novartis Reportedly Taps Centerview to Evaluate Options for Dermatology Business TheStreet.com
02:49PM  Why Juno Therapeutics Shares Are Going Up 21.2% Today Motley Fool
10:19AM  Conatus (CNAT) Loss Wider Than Expected in Q3, Sales Miss Zacks
09:05AM  Now that Novartis is buying AAA, Im zeroing in on this potential pharma target MarketWatch
09:03AM  Juno Therapeutics' 3rd Quarter Boosted by Potential Rival Novartis Motley Fool
07:10AM  Earnings Review and Free Research Report: Novartis Sales Grew 2%; EPS Jumped 10% ACCESSWIRE
05:30AM  Teva earnings: Facing down cheaper generic prices, generic competition of its own and a lot of debt MarketWatch
01:00AM  Juno touts latest cancer drug results after rivals win FDA approval American City Business Journals
Nov-01-17 04:02PM  How Blood-Disease Data Sent These 2 Biotech Stocks Flying Investor's Business Daily
09:46AM  Can Juno Therapeutics Outmaneuver Its CAR-T Competitors? Motley Fool
09:14AM  Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease PR Newswire
05:38AM  Novartis Weighs Sale of Dermatology Generics Business Bloomberg
Oct-31-17 08:13PM  Bayer, Novartis clash with UK doctors over use of cheap eye drug Reuters
04:51PM  Novartis Buys French Radiopharmaceutical Company Zacks
08:59AM  Advanced Accelerator (AAAP) in Focus: Stock Moves 10.4% Higher Zacks
08:10AM  Today's Research Reports on Stocks to Watch: Merck & Co. and Novartis ACCESSWIRE
03:34AM  Novartis asks FDA to expand Kymriah's use against blood cancer Reuters
Oct-30-17 04:06PM  Lennar, Strayer, Dynegy Announce Deals; These May Be Next Investor's Business Daily
01:35PM  [$$] Novartis to buy French nuclear medicine group AAA Financial Times
01:10PM  Stocks Burrow Further Into the Red on Logistics of Tax Cut Plan TheStreet.com
12:49PM  [$$] Novartis/Advanced Accelerator: hot metal type Financial Times
12:36PM  Why Advanced Accelerator Applications SA Acquired a Higher Price Today Motley Fool
11:08AM  Merck Weighs on Dow but Apple and Tech Rally Give Lift to Nasdaq TheStreet.com
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segments also franchises ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic, and other medicines, as well as cell and gene therapies. The Sandoz segment offers active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The Alcon segment offers eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses for use in surgical procedures to treat cataracts, vitreoretinal conditions, glaucoma, and refractive errors; and contact lenses and lens care products. The company has collaboration and licensing agreements with Xencor for the development of bispecific antibodies for treating cancer; and Surface Oncology to access four pre-clinical programs in immuno-oncology. It also has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and Caribou Biosciences for the development of drug discovery tools. In addition, the company has a clinical research collaboration with Bristol-Myers Squibb Company to investigate Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen in combination with Mekinist as a treatment option for metastatic colorectal cancer. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerJul 05Buy15.00266,6674,000,0052,544,182Jul 05 06:05 PM
Novartis Bioventures Ltd10% OwnerJun 19Sale22.023,22070,8992,251,457Jun 20 04:41 PM
Novartis Bioventures Ltd10% OwnerJun 16Sale21.2453,2001,130,2072,254,677Jun 20 04:41 PM
Novartis Bioventures Ltd10% OwnerJun 08Sale22.0070015,4002,307,877Jun 12 04:12 PM
Novartis Bioventures Ltd10% OwnerJun 07Sale22.114,840106,9992,308,577Jun 08 04:33 PM
Novartis Bioventures Ltd10% OwnerJun 06Sale22.987,274167,1612,313,417Jun 08 04:33 PM
Novartis Bioventures Ltd10% OwnerJun 05Sale23.114,780110,4882,320,691Jun 06 04:27 PM
Novartis Bioventures Ltd10% OwnerJun 02Sale23.4714,867348,9492,325,471Jun 06 04:27 PM
Novartis Bioventures Ltd10% OwnerJun 01Sale23.8910,722256,1762,340,338Jun 02 04:25 PM
Novartis Bioventures Ltd10% OwnerMay 31Sale23.9435,539850,8962,351,060Jun 02 04:25 PM
Novartis Bioventures Ltd10% OwnerMay 26Sale25.145,300133,2672,386,599May 30 04:29 PM
Novartis Bioventures Ltd10% OwnerMay 25Sale25.00531,3252,391,899May 30 04:29 PM
Novartis Bioventures Ltd10% OwnerMay 24Sale25.0117,451436,3642,391,952May 25 04:57 PM
Novartis Bioventures Ltd10% OwnerMay 18Sale25.509,019229,9642,409,403May 22 06:50 PM
Novartis Bioventures Ltd10% OwnerMay 17Sale25.5122,534574,9012,418,422May 18 04:36 PM
Novartis Bioventures Ltd10% OwnerMay 16Sale26.3320,081528,7252,440,956May 18 04:36 PM
Novartis Bioventures Ltd10% OwnerMar 15Buy5.00560,0002,800,0005,805,550Mar 17 08:36 PM
Novartis Bioventures Ltd10% OwnerMar 01Sale20.917,778162,6582,461,037May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 28Sale20.867,847163,6702,468,815May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 27Sale20.9657,8441,212,3062,476,662May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 24Sale20.935,398113,0002,534,506May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 23Sale21.044,999105,1602,539,904May 02 05:22 PM
Novartis Bioventures Ltd10% OwnerFeb 22Sale21.8674916,3702,544,903May 02 05:22 PM